Finanzen von aTyr Pharma Inc (ATYR)ATYRaTyr Pharma Inc

Evaluating the bottom line, aTyr Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.37%, provide a clear picture of how effectively ATYR converts its operational activities into shareholder value.

In the context of the broader market, ATYR competes directly with industry leaders such as PBM and BYSI. With a market capitalization of $484.56M, it holds a leading position in the sector. When comparing efficiency, ATYR's gross margin of N/A stands against PBM's N/A and BYSI's N/A. Such benchmarking helps identify whether aTyr Pharma Inc is trading at a premium or discount relative to its financial performance.

aTyr Pharma has reported zero revenue for several quarters, with a net loss of $10.31 million in Q2 2026, down from $19.53 million in the previous year, indicating some improvement but still significant losses. The gross margin is 100% for Q3 2025 but has been zero in other quarters, reflecting inconsistent performance.